+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Experimental immunotherapy of colorectal carcinoma by monoclonal antibody ND4

Experimental immunotherapy of colorectal carcinoma by monoclonal antibody ND4

Hybridoma 26(1): 10-16

The potential for experimental immunotherapy of colorectal cancers by mouse IgG2a monoclonal antibody (MAb) ND4 is investigated. The MAb ND4 recognizes a 160 kd cell surface glycoprotein that is strongly expressed in 58% of colorectal carcinomas. The antibody is internalizable by MIP-101 colorectal carcinoma cells. Biodistribution studies in nude mice bearing MIP-101 subcutaneous tumors showed accumulation of 125I-ND4 MAb in tumors from 5% at 18 hours to 14% of the injected dose per gram tissue at 14 days after intraperitoneal (i.p.) injection. Experimental immunotherapy studies using 125I-ND4 in MIP-101 tumor-bearing nude mice showed 64% inhibition of tumor growth 2 weeks after two i.p. injections at 7-day intervals. The MAb ND4 may be useful as a therapeutic reagent for colorectal tumors.

(PDF emailed within 0-6 h: $19.90)

Accession: 012971903

Download citation: RISBibTeXText

PMID: 17316080

DOI: 10.1089/hyb.2006.036

Related references

BAT monoclonal antibody immunotherapy of human metastatic colorectal carcinoma in mice. Cancer Letters 229(2): 217-222, 2005

Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Cancer 86(1): 22-30, July 1, 1999

Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. Journal of Nuclear Medicine 36(3): 420-429, 1995

Tumoricidal activity of an anti-human colorectal carcinoma monoclonal antibody on colorectal carcinoma xenograft in athymic mice. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 238, 1997

Indium-labeled anti-colorectal carcinoma monoclonal antibody accumulation in non-tumored tissue in patients with colorectal carcinoma. Journal of Nuclear Medicine 31(12): 1975-1979, 1990

Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1. Anticancer Research 21(1b): 621-627, 2001

Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro. Biological & Pharmaceutical Bulletin 31(12): 2288-2293, 2008

Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer. Japanese Journal of Cancer Research 91(8): 817-824, August, 2000

Initial clinical study of a new indium labeled anti colorectal carcinoma monoclonal antibody mab 1a3 in patients with advanced colorectal cancer. Journal of Nuclear Medicine 32(5 SUPPL): 1054, 1991

Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494. Deutsche Medizinische Wochenschrift 113(10): 374-380, 1988

Monoclonal antibody preparations for immunotherapy of experimental GBS infection. Antibiotics and ChemoTherapy 35: 254-266, 1985

Immunotherapy of advanced carcinoma of the pancreas with the monoclonal antibody bw494. DMW (Deutsche Medizinische Wochenschrift) 113(10): 374-380, 1988

Pancreatic carcinoma is there a role for immunotherapy with a monoclonal antibody to the egf receptor?. Gastroenterology 102(4 PART 2): A298, 1992

Imaging of primary and metastatic colorectal carcinoma with monoclonal antibody 791T/36 and the therapeutic potential of antibody-drug conjugates. Cancer Detection and Prevention. Supplement 1: 249-262, 1987